by Team Small News | Jan 27, 2026 | Pharma, Zydus
Zydus Lifesciences, a leading life sciences company, has launched the world’s first biosimilar of nivolumab in India under the brand name Tishtha. This milestone marks a significant expansion of patient access to cutting-edge cancer therapies, particularly in...
by Team Small News | Jan 26, 2026 | Cipla, Pharma, Sun Pharma, Zydus
Several major pharmaceutical companies, including Sun Pharma, Cipla, Zydus, and Graviti Pharmaceuticals, are recalling various products in the US due to manufacturing issues, according to recent US FDA enforcement reports. The recalls are primarily related to problems...
by Team Small News | Jan 25, 2026 | Pharma, Zydus
The Zydus Pinkathon, a prominent women’s running event, is set to return to Bengaluru on January 25, marking its eighth edition in the city after a seven-year hiatus. With an expected participation of over 5,000 women, the event aims to promote fitness and...
by Team Small News | Jan 24, 2026 | Pharma, Zydus
The US Food and Drug Administration (USFDA) has completed an inspection at Zydus Cadila’s manufacturing facility in Ankleshwar, Gujarat, with three observations. The inspection was conducted from February 13 to February 17, 2023. Although the company has not...
by Team Small News | Jan 15, 2026 | Cipla, Lupin, Pharma, Sun Pharma, Zydus
The Indian pharmaceutical industry is bracing for a challenging earnings season in Q3, with expectations of muted margins due to the loss of patent exclusivity for the blockbuster blood cancer drug Revlimid in the US. Revlimid, which has generated over $100 billion in...
by Team Small News | Jan 13, 2026 | Pharma, Zydus
The Delhi High Court has given a significant ruling in favor of Zydus, a pharmaceutical company, allowing it to sell a biosimilar version of the cancer drug Nivolumab at a lower price. Nivolumab, marketed under the brand name Opdivo by Bristol Myers Squibb, is a...